Home Markets Earnings Estimate Forecast on Incyte Corporation(INCY)

Earnings Estimate Forecast on Incyte Corporation(INCY)


Incyte Corporation(INCY): For the most recent quarter end, Incyte Corporation reported Annual Earnings of $0.15. Based on the filings, last years Annual Earnings was, $0.61. For the most recent quarter end, INCY reported a surprise Earnings per Share of 7.14% . The consensus estimate for current quarter is $-0.65 and for the current fiscal year, the estimate is $0.66. For the Next fiscal year, the estimate is $0.99 based on the consensus. Wilmington based Incyte Corporation Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on May 08, 2017.

Incyte Corporation has received $-0.65 as the consensus Earnings Estimate for the Quarter ending on Mar 2017 ,According to the estimate provided by 8 Financial Advisor in the Stock Trading Firms. Among 8 Analysts, Bottom line EPS Estimate for the current quarter is $-0.82 while the top line estimate is $-0.46 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -641.67%. Incyte Corporation reported better than expected with a surprise EPS of 7.14% or $0.01 during its most recent quarterly earnings. The Actual EPS was $0.15 compared to the Estimated EPS of $0.14. According to the corporate earnings calendar, Incyte Corporation will release next earnings on May 08, 2017 with an estimated EPS consensus of $-0.65. Based on the consensus of stock financial advisors the stock has a price target of $127.58. Current year estimate on EPS consensus is $0.66.

Incyte Corporation has a Price to Earnings ratio of 218.5 for the trailing twelve month period. The price to book ratio of the company for the most recent quarter is 54.95. For the Most Recent Fiscal Year, Incyte Corporation has a price to cash ratio of 130.91. For the Trailing twelve month period, company showed a Net Profit Margin of 9.43% and Return on Equity of the stock is 32.88%.

For Dividend Investing Stock Market Traders Incyte Corporation has a Dividend Yield of 0% with an Annual Dividend of $0. It has a Payout Ratio of 0 and the change in Dividend payout ratio is .

Incyte Corporation Last issued its quarterly earnings results on Feb 14, 2017. The company reported $0.05 EPS for the quarter, missing the analyst consensus estimate by $ -0.18. Analyst had a consensus of $0.23. The company had revenue of $326.50 million for the quarter, compared to analysts expectations of $327.14 million. The companys revenue was up 33.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.29 EPS.

Company has reported several Insider transactions to the SEC, on Jan 11, 2017, Reid M Huber (EVP, Chief Scientific Officer) sold 11,739 shares at 113.55 per share price.On Nov 17, 2016, Paula J Swain (EVP, Human Resources) sold 10,000 shares at 103.26 per share price.On Oct 11, 2016, Barry P Flannelly (EVP & General Manager US) sold 24,204 shares at 97.00 per share price.

Incyte Corporation (NASDAQ:INCY) witnessed a decline in the market cap on Wednesday as its shares dropped 0.82% or 1 points. After the session commenced at $121.7, the stock reached the higher end at $122.9 while it hit a low of $121.25. With the volume soaring to 854,934 shares, the last trade was called at $121.36. The company has a 52-week high of $125.49. The company has a market cap of $22,987 million and there are 189,408,380 shares in outstanding. The 52-week low of the share price is $60.3.

Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of new small molecule drugs for cancer and inflammation. Incyte also has strategic alliances with Lexicon Genetics and Medarex focused on the discovery and development of protein therapeutics or antibodies to treat inflammatory diseases and cancer.



Please enter your comment!
Please enter your name here